AIOS margins require near-zero clinician time

This margin story only works if AIOS turns obesity care from a clinician service into a software supervised workflow. Today the core job still needs a licensed prescriber to review the intake, decide if GLP-1 treatment is appropriate, handle dose changes, and remain accountable for safety. That means every new patient still pulls real labor into the system, even if AIOS automates most of the form filling, follow ups, and messaging around that decision.

• GLP-1 telehealth is not a one time script business. Ongoing obesity care means titration, side effect checks, refill decisions, and periodic monitoring. That is why peers like Ro built labs, pharmacy, and care operations around the prescription, and why AIOS cannot remove humans from the loop without changing the care model itself.
  5 sacra 6 fda
• The regulatory bottleneck is concrete. In the UK, remote prescribing guidance says the prescriber is responsible for the decision and must have adequate knowledge of the patient. EU cross border prescription rules also center the named doctor and signature. That keeps accountability attached to a licensed person, not an autonomous agent.
  2 gmcuk 3 europa 7 gmcuk
• This is also why scale does not automatically create software margins. AIOS reached a $420M revenue run rate by June 2026, but local competitor sets like Numan and Yazen still operate as regulated care businesses with clinicians embedded in the workflow. The winning system is the one that compresses clinician minutes most, not the one that removes them entirely.
  1 sacra 4 sacra 8 sacra 9 sacra

The next phase is a race to make each clinician responsible for far more patients without ever giving up formal human sign off. The companies that win will use software to shrink review time to a quick exception check, then spread that operating model market by market as regulators slowly define what safe AI assisted prescribing looks like.